5-Hydroxyindoleacetic Acid, Random, Urine - Beebe Healthcare Laboratory Services

Ordering Guidance

This test uses a random urine collection to assess 5-hydroxyindoleacetic acid concentrations. If a 24-hour urine collection is preferred, order HIAA / 5-Hydroxyindoleacetic Acid, 24 Hour, Urine.

Necessary Information

Patient's age and sex are required.

Specimen Required

Patient Preparation:

1. Some medications could interfere with test results. The ordering provider should decide if any medications should be stopped and when they should be restarted. If clinically feasible, discontinue the following medications at least 48 hours prior to specimen collection:

-Acetaminophen (Tylenol or generic versions)

-Tryptophan containing supplements

2. For 48 hours prior to the urine collection, the patient should:

Limit the following to one serving per day:

-Fruits

-Vegetables

-Nuts

-Caffeinated beverages or foods

Supplies: Urine Tubes, 10 mL (T068)

Container/Tube: Plastic, 10-mL urine tube

Specimen Volume: 5 mL

Collection Instructions:

1. Collect a random urine specimen.

2. Store and send refrigerate

Useful For

Biochemical diagnosis and monitoring of intestinal carcinoid syndrome using random urine specimens

Method Name

Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)

Reporting Name

5-HIAA, Random, U

Specimen Type

Urine

Specimen Minimum Volume

2 mL

Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Urine	Refrigerated (preferred)	56 days
	Frozen	365 days

Reference Values

5-HIAA, mg/g creatinine 99th percentile cutoff
Age	Female	Male
≤23 months	≤17.53	≤16.42
24-35 months	≤17.07	≤15.96
3 years	≤16.70	≤15.60
4 years	≤16.03	≤14.93
5 years	≤15.26	≤14.17
6 years	≤14.40	≤13.34
7 years	≤13.47	≤12.43
8 years	≤12.52	≤11.52
9 years	≤11.58	≤10.63
10 years	≤10.67	≤9.79
11 years	≤9.81	≤9.00
12 years	≤9.02	≤8.29
13 years	≤8.32	≤7.65
14 years	≤7.70	≤7.08
15 years	≤7.16	≤6.59
16 years	≤6.72	≤6.15
17 years	≤6.36	≤5.78
18 years	≤6.08	≤5.45
19 years	≤5.88	≤5.17
20 years	≤5.73	≤4.93
21 years	≤5.64	≤4.73
22 years	≤5.59	≤4.55
23 years	≤5.57	≤4.40
24 years	≤5.57	≤4.28
25 years	≤5.58	≤4.19
26 years	≤5.61	≤4.11
27 years	≤5.64	≤4.06
28 years	≤5.67	≤4.03
29 years	≤5.70	≤4.02
30 years	≤5.72	≤4.01
31 years	≤5.75	≤4.02
32 years	≤5.77	≤4.03
33 years	≤5.78	≤4.05
34 years	≤5.79	≤4.06
35 years	≤5.80	≤4.08
36 years	≤5.80	≤4.09
37 years	≤5.80	≤4.11
38 years	≤5.80	≤4.12
39 years	≤5.81	≤4.14
40 years	≤5.82	≤4.17
41 years	≤5.85	≤4.22
42 years	≤5.89	≤4.27
43 years	≤5.95	≤4.35
44 years	≤6.04	≤4.43
45 years	≤6.14	≤4.53
46 years	≤6.26	≤4.63
47 years	≤6.40	≤4.75
48 years	≤6.55	≤4.86
49 years	≤6.71	≤4.99
50 years	≤6.86	≤5.11
51 years	≤7.01	≤5.24
52 years	≤7.15	≤5.37
53 years	≤7.29	≤5.51
54 years	≤7.41	≤5.64
55 years	≤7.52	≤5.78
56 years	≤7.62	≤5.91
57 years	≤7.71	≤6.05
58 years	≤7.80	≤6.17
59 years	≤7.88	≤6.29
60 years	≤7.95	≤6.41
61 years	≤8.02	≤6.51
62 years	≤8.09	≤6.60
63 years	≤8.15	≤6.69
64 years	≤8.21	≤6.76
65 years	≤8.28	≤6.82
66 years	≤8.34	≤6.88
67 years	≤8.40	≤6.93
68 years	≤8.46	≤6.97
69 years	≤8.52	≤7.00
70 years	≤8.58	≤7.03
71 years	≤8.65	≤7.06
72 years	≤8.71	≤7.08
73 years	≤8.77	≤7.10
74 years	≤8.82	≤7.11
75 years	≤8.86	≤7.11
76 years	≤8.90	≤7.11
77 years	≤8.92	≤7.10
78 years	≤8.93	≤7.09
79 years	≤8.93	≤7.07
80 years	≤8.92	≤7.05
81 years	≤8.90	≤7.02
82 years	≤8.88	≤7.00
83 years	≤8.86	≤6.98
84 years	≤8.85	≤6.97
85 years	≤8.84	≤6.95
86 years	≤8.84	≤6.94
87 years	≤8.84	≤6.94
88 years	≤8.84	≤6.94
>or= 89 years	≤8.85	≤6.93

Interpretation

If pharmacological and dietary artifacts have been ruled out, an elevated excretion of 5-hydroxyindoleacetic acid is a probable indicator of the presence of a serotonin-producing tumor.

Clinical Reference

1. Grimaldi F, Fazio N, Attanasio R, et al. Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms. J Endocrinol Invest. 2014;37(9):875-909. doi:10.1007/s40618-014-0119-0

2. Vinik A, Hughes MS. Feliberti E, et al. Carcinoid tumors. In: Feingold KR, Anawalt B, Boyce A, et al, eds. Endotext [Internet]. MDText.com, Inc; 2000. Updated February 5, 2018. Accessed March 17, 2023. Available at www.ncbi.nlm.nih.gov/books/NBK279162/

3. Shah D, Mandot A, Cerejo C, Amarapurkar D, Pal A: The outcome of primary hepatic neuroendocrine tumors: A single-center experience. J Clin Exp Hepatol. 2019;9(6):710-715. doi: 10.1016/j.jceh.2019.08.002

4. Perry D, Hayek SS: Carcinoid heart disease. A guide for clinicians. Cardiol Clin. 2019;37(4):497-503. doi:10.1016/j.ccl.2019.07.014

5. Degnan AJ, Tocchio S, Kurtom W, Tadros SS. Pediatric neuroendocrine carcinoid tumors: Management, pathology, and imaging findings in a pediatric referral center. Pediatr Blood Cancer. 2017;64(9). doi:10.1002/pbc.26477

6. Corcuff JB, Chardon L, El Hajji Ridah I, Brossaud J. Urinary sampling for 5HIAA and metanephrines determination: revisiting the recommendations. Endocr Connect. 2017;6(6):R87-R98. doi:10.1530/EC-17-0071

Day(s) Performed

Monday through Friday

Report Available

2 to 4 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

83497

LOINC Code Information

Test ID	Test Order Name	Order LOINC Value
HIAAR	5-HIAA, Random, U	11145-0

Result ID	Test Result Name	Result LOINC Value
616090	5-HIAA, Random, U	11145-0

Beebe Healthcare Laboratory Services powered by Mayo Clinic Laboratories

Search

Browse by Name

Test Code HIAAR 5-Hydroxyindoleacetic Acid, Random, Urine